BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35681700)

  • 1. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options.
    Hescheler DA; Hartmann MJM; Riemann B; Michel M; Bruns CJ; Alakus H; Chiapponi C
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic thyroid cancer: genome-based search for new targeted therapy options.
    Hescheler DA; Hartmann MJM; Riemann B; Michel M; Bruns CJ; Alakus H; Chiapponi C
    Endocr Connect; 2022 Apr; 11(4):. PubMed ID: 35275096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.
    De Martino MC; Al Ghuzlan A; Aubert S; Assié G; Scoazec JY; Leboulleux S; Do Cao C; Libè R; Nozières C; Lombès M; Pattou F; Borson-Chazot F; Hescot S; Mazoyer C; Young J; Borget I; Colao A; Pivonello R; Soria JC; Bertherat J; Schlumberger M; Lacroix L; Baudin E
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4080-8. PubMed ID: 23979958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
    Hescheler DA; Plum PS; Zander T; Quaas A; Korenkov M; Gassa A; Michel M; Bruns CJ; Alakus H
    Gastric Cancer; 2020 Jul; 23(4):627-638. PubMed ID: 32107691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
    Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of adrenocortical carcinoma.
    Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
    [No Abstract]   [Full Text] [Related]  

  • 8. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
    Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
    Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
    Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
    Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
    Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.
    Fiorentini C; Grisanti S; Cosentini D; Abate A; Rossini E; Berruti A; Sigala S
    J Oncol; 2019; 2019():6072863. PubMed ID: 31057613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges.
    Cherradi N
    Front Endocrinol (Lausanne); 2015; 6():195. PubMed ID: 26834703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocortical Carcinoma Steroid Profiles:
    Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
    Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of developmental therapeutics for adrenocortical carcinoma.
    Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
    Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.
    Ikeya A; Nakashima M; Yamashita M; Kakizawa K; Okawa Y; Saitsu H; Sasaki S; Sasano H; Suda T; Oki Y
    PLoS One; 2020; 15(4):e0231665. PubMed ID: 32287321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.
    Choonoo G; Blucher AS; Higgins S; Boardman M; Jeng S; Zheng C; Jacobs J; Anderson A; Chamberlin S; Evans N; Vigoda M; Cordier B; Tyner JW; Kulesz-Martin M; McWeeney SK; Laderas T
    PLoS One; 2019; 14(10):e0223639. PubMed ID: 31596908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.
    Lavoie JM; Csizmok V; Williamson LM; Culibrk L; Wang G; Marra MA; Laskin J; Jones SJM; Renouf DJ; Kollmannsberger CK
    Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.